1
|
Shukla MK, Wilkes P, Bargary N, Meagher K, Khamar D, Bailey D, Hudson SP. Identification of monoclonal antibody drug substances using non-destructive Raman spectroscopy. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2023; 299:122872. [PMID: 37209478 DOI: 10.1016/j.saa.2023.122872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/26/2023] [Revised: 05/05/2023] [Accepted: 05/10/2023] [Indexed: 05/22/2023]
Abstract
Monoclonal antibodies provide highly specific and effective therapies for the treatment of chronic diseases. These protein-based therapeutics, or drug substances, are transported in single used plastic packaging to fill finish sites. According to good manufacturing practice guidelines, each drug substance needs to be identified before manufacturing of the drug product. However, considering their complex structure, it is challenging to correctly identify therapeutic proteins in an efficient manner. Common analytical techniques for therapeutic protein identification are SDS-gel electrophoresis, enzyme linked immunosorbent assays, high performance liquid chromatography and mass spectrometry-based assays. Although effective in correctly identifying the protein therapeutic, most of these techniques need extensive sample preparation and removal of samples from their containers. This step not only risks contamination but the sample taken for the identification is destroyed and cannot be re-used. Moreover, these techniques are often time consuming, sometimes taking several days to process. Here, we address these challenges by developing a rapid and non-destructive identification technique for monoclonal antibody-based drug substances. Raman spectroscopy in combination with chemometrics were used to identify three monoclonal antibody drug substances. This study explored the impact of laser exposure, time out of refrigerator and multiple freeze thaw cycles on the stability of monoclonal antibodies. and demonstrated the potential of using Raman spectroscopy for the identification of protein-based drug substances in the biopharmaceutical industry.
Collapse
Affiliation(s)
- Mahendra K Shukla
- SSPC, The Science Foundation Ireland Research Centre for Pharmaceuticals & Bernal Institute, University of Limerick, Limerick V94 T9PX, Ireland; Department of Chemical Sciences, University of Limerick, Limerick V94 T9PX, Ireland
| | - Philippa Wilkes
- SSPC, The Science Foundation Ireland Research Centre for Pharmaceuticals & Bernal Institute, University of Limerick, Limerick V94 T9PX, Ireland; Department of Mathematics and Statistics, University of Limerick, Limerick V94 T9PX, Ireland
| | - Norma Bargary
- SSPC, The Science Foundation Ireland Research Centre for Pharmaceuticals & Bernal Institute, University of Limerick, Limerick V94 T9PX, Ireland; Department of Mathematics and Statistics, University of Limerick, Limerick V94 T9PX, Ireland
| | - Katherine Meagher
- Manufacturing Science and Technology, Sanofi Ireland, Old Kilmeaden Road, Waterford, Ireland
| | - Dikshitkumar Khamar
- Manufacturing Science and Technology, Sanofi Ireland, Old Kilmeaden Road, Waterford, Ireland
| | - Donal Bailey
- Manufacturing Science and Technology, Sanofi Ireland, Old Kilmeaden Road, Waterford, Ireland
| | - Sarah P Hudson
- SSPC, The Science Foundation Ireland Research Centre for Pharmaceuticals & Bernal Institute, University of Limerick, Limerick V94 T9PX, Ireland; Department of Mathematics and Statistics, University of Limerick, Limerick V94 T9PX, Ireland.
| |
Collapse
|
2
|
Dumoncel RFP, Xavier B, Cardoso Júnior CDA, da Silva FS, Motta LGJ, Cavalheiro TN, Dalmora SL. Analysis of Denosumab by a Validated CZE Method and Determination of Sialic Acids by the RP-HPLC Method. J Chromatogr Sci 2023; 61:177-185. [PMID: 35279712 DOI: 10.1093/chromsci/bmac019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Indexed: 11/14/2022]
Abstract
A capillary zone electrophoresis (CZE) method was developed and validated to quantitate the monoclonal antibody denosumab (DmAb) and its charge variants in pharmaceutical products, demonstrating excellent precision, linearity and accuracy. Separations were obtained with migration times of 11.3 min for DmAb and the calibration curve was linear in the range of 0.95-20 mg/mL. The analytical comparability of seven batches of Prolia® showed mean differences of the estimated content/potencies of 1.87% lower, and 0.84 and 1.21% higher compared with the size-exclusion and reversed-phase liquid chromatography (SE-HPLC and RP-HPLC) methods and the osteoclast antiproliferative bioassay, respectively, with non-significant differences (P > 0.05). An RP-HPLC method with fluorescence detection (RP-HPLC-F), performed on a Kinetex® EVO C18 column (5 μm, 100 Å, 250 mm × 4.6 mm), was optimized to determine the levels of sialic acids of DmAb biomolecules, giving mean concentrations of 0.16 and 0.17 μg N-acetylneuraminic acid/mg DmAb for Prolia® and Xgeva® pharmaceutical products, respectively. The results demonstrated the capability of each one of the methods, and their use in combination constitutes a strategy to monitor instability, thereby assuring the quality and the batch-to-batch consistency of the biotechnology-derived medicine.
Collapse
Affiliation(s)
- Rafaela Ferreira Perobelli Dumoncel
- Postgraduate Program in Pharmaceutical Sciences, Industrial Pharmacy Department, Federal University of Santa Maria, Santa Maria, RS 97105-900, Brazil
| | - Bruna Xavier
- Postgraduate Program in Pharmaceutical Sciences, Industrial Pharmacy Department, Federal University of Santa Maria, Santa Maria, RS 97105-900, Brazil
| | - Clóvis Dervil Appratto Cardoso Júnior
- Postgraduate Program in Pharmaceutical Sciences, Industrial Pharmacy Department, Federal University of Santa Maria, Santa Maria, RS 97105-900, Brazil
| | - Francielle Santos da Silva
- Postgraduate Program in Pharmaceutical Sciences, Industrial Pharmacy Department, Federal University of Santa Maria, Santa Maria, RS 97105-900, Brazil
| | - Luís Gustavo Jung Motta
- Industrial Pharmacy Department, Federal University of Santa Maria, Santa Maria, RS 97105-900, Brazil
| | - Thaís Neuhaus Cavalheiro
- Industrial Pharmacy Department, Federal University of Santa Maria, Santa Maria, RS 97105-900, Brazil
| | - Sérgio Luiz Dalmora
- Industrial Pharmacy Department, Federal University of Santa Maria, Santa Maria, RS 97105-900, Brazil
| |
Collapse
|
3
|
Lipid-lowering activity and mechanism of peptides from jellyfish Nemopilema nomurai. J Funct Foods 2023. [DOI: 10.1016/j.jff.2023.105421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
|
4
|
Gurram S, Srivastava G, Badve V, Nandre V, Gundu S, Doshi P. Pyridine Borane as Alternative Reducing Agent to Sodium Cyanoborohydride for the PEGylation of L-asparaginase. Appl Biochem Biotechnol 2022; 194:827-847. [PMID: 34550501 DOI: 10.1007/s12010-021-03657-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2021] [Accepted: 09/03/2021] [Indexed: 11/30/2022]
Abstract
PEGylation is a reductive alkylation of a protein N-terminal/α-amine of protein with mPEG chain by reducing agent. To obtain quantitative and site-specific PEGylation, sodium cyanoborohydride is commonly used as a reducing agent. The reduction process of sodium cyanoborohydride produces highly poisonous hydrogen cyanide, which may render the final product toxic. Herein, we have studied various reducing agents such as dimethylamine borane, triethylamine borane, trimethylamine borane, pyridine borane, morpholine borane, 2-picoline borane, and 5-ethyl-2-methyl-pyridine borane were tested as alternatives to sodium cyanoborohydride for the PEGylation of L-asparaginase. The characterization of reacted pegaspargase was carried out by SDS-PAGE, Western blotting, SEC-HPLC, RP-HPLC, SEC-MALS, CD, enzyme activity, and cell proliferation assays using with lymphoblast cells and MTS/PMS as substrate. Pyridine borane was determined to be the best acceptable reducing agent for PEGylation in terms of purity and activity. As a result, instead of sodium cyanoborohydride, pyridine borane can be employed.
Collapse
Affiliation(s)
- Santosh Gurram
- Division of Biochemistry, Department of Chemistry, Savitribai Phule Pune University, Formerly University of Pune), Ganeshkhind, Pune, 411007, Maharashtra, India
| | - Gopal Srivastava
- Division of Biochemistry, Department of Chemistry, Savitribai Phule Pune University, Formerly University of Pune), Ganeshkhind, Pune, 411007, Maharashtra, India
| | - Vishnupriya Badve
- Division of Biochemistry, Department of Chemistry, Savitribai Phule Pune University, Formerly University of Pune), Ganeshkhind, Pune, 411007, Maharashtra, India
| | - Vinod Nandre
- Division of Biochemistry, Department of Chemistry, Savitribai Phule Pune University, Formerly University of Pune), Ganeshkhind, Pune, 411007, Maharashtra, India
| | - Shridevi Gundu
- Division of Biochemistry, Department of Chemistry, Savitribai Phule Pune University, Formerly University of Pune), Ganeshkhind, Pune, 411007, Maharashtra, India
| | - Pooja Doshi
- Division of Biochemistry, Department of Chemistry, Savitribai Phule Pune University, Formerly University of Pune), Ganeshkhind, Pune, 411007, Maharashtra, India.
| |
Collapse
|
5
|
Makki AA, Massot V, Byrne HJ, Respaud R, Bertrand D, Mohammed E, Chourpa I, Bonnier F. Understanding the discrimination and quantification of monoclonal antibodies preparations using Raman spectroscopy. J Pharm Biomed Anal 2020; 194:113734. [PMID: 33243491 DOI: 10.1016/j.jpba.2020.113734] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 10/22/2020] [Accepted: 10/26/2020] [Indexed: 11/19/2022]
Abstract
The use of Raman spectroscopy for analytical quality control of anticancer drug preparations in clinical pharmaceutical dispensing units is increasing in popularity, notably supported by commercially available, purpose designed instruments. Although not legislatively compulsory, analytical methods are frequently used post-preparation to verify the accuracy of a preparation in terms of identity and quantity of the drug in solution. However, while the rapid, cost effective and label free analysis achieved with Raman spectroscopy is appealing, it is important to understand the molecular origin of the spectral contributions collected from the solution of actives and excipients, to evaluate the strength and limitation for the technique, which can be used to identify and quantify either the prescribed commercial formulation, and/or the active drug itself, in personalised solutions. In the current study, four commercial formulations, Erbitux®, Truxima®, Ontruzant® and Avastin® of monoclonal antibodies (mAbs), corresponding respectively to cetuximab, rituximab, trastuzumab and bevacizumab have been used to highlight the key role of excipients in discrimination and quantification of the formulations. It is demonstrated that protein based anticancer drugs such as mAbs have a relatively weak Raman response, while excipients such as glycine, trehalose or histidine contribute significantly to the spectra. Multivariate analysis (partial least square regression and partial least square discriminant analysis) further demonstrates that the signatures of the mAbs themselves are not prominent in mathematical models and that those of the excipients are solely responsible for the differentiation of formulation and accurate determination of concentrations. While Raman spectroscopy can successfully validate the conformity of mAbs intravenous infusion solutions, the basis for the analysis should be considered, and special caution should be given to excipient compositions in commercial formulations to ensure reliability and reproducibility of the analysis.
Collapse
Affiliation(s)
- Alaa A Makki
- Université de Tours, EA 6295 Nanomédicaments et Nanosondes, 31 avenue Monge, 37200 Tours, France; Faculty of Pharmacy, University of Gezira, P.O. Box 20, 21111 Wad Madani, Sudan
| | - Victor Massot
- Unité de Biopharmacie Clinique Oncologique, Pharmacie, CHU de Tours, France
| | - Hugh J Byrne
- FOCAS Research Institute, Technological University Dublin, City Campus, Kevin Street, Dublin 8, Ireland
| | - Renaud Respaud
- Université de Tours, UMR 1100, CHRU de Tours, Service de Pharmacie, F-37032 Tours, France
| | | | - Elhadi Mohammed
- Faculty of Pharmacy, University of Gezira, P.O. Box 20, 21111 Wad Madani, Sudan
| | - Igor Chourpa
- Université de Tours, EA 6295 Nanomédicaments et Nanosondes, 31 avenue Monge, 37200 Tours, France
| | - Franck Bonnier
- Université de Tours, EA 6295 Nanomédicaments et Nanosondes, 31 avenue Monge, 37200 Tours, France.
| |
Collapse
|
6
|
Content/Potency Assessment of Botulinum Neurotoxin Type-A by Validated Liquid Chromatography Methods and Bioassays. Toxins (Basel) 2019; 11:toxins11010035. [PMID: 30642048 PMCID: PMC6356430 DOI: 10.3390/toxins11010035] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2018] [Revised: 12/28/2018] [Accepted: 01/10/2019] [Indexed: 01/16/2023] Open
Abstract
Botulinum neurotoxin type-A (BoNTA) is one of the seven different serotypes (A to G) produced by Clostridium botulinum. A stability-indicating size-exclusion chromatography (SEC) method was developed and validated, and the specificity was confirmed by forced degradation study, interference of the excipients, and peaks purity. The method was applied to assess the content and high-molecular-weight (HMW) forms of BoNTA in biopharmaceutical products, and the results were compared with those of the LD50 mouse bioassay, the T−47D cell culture assay, and the reversed-phase chromatography (RPC) method, giving mean values of 0.71% higher, 0.36% lower, and 0.87% higher, respectively. Aggregated forms showed significant effects on cytotoxicity, as well as a decrease in the bioactivity (p < 0.05). The employment of the proposed method in conjunction with the optimized analytical technologies for the analysis of the intact and altered forms of the biotechnology-derived medicines, in the correlation studies, enabled the demonstration of the capability of each one of the methods and allowed for great improvements, thereby assuring their safe and effective use.
Collapse
|